Biogen Inc., known by its stock symbol BIIB, is a leading multinational biotechnology company based in the United States. The company was originally founded in 1978 in Geneva, Switzerland, and is now headquartered in Cambridge, Massachusetts. Biogen has gained recognition as one of the world’s oldest independent biotechnology companies, with a reputation for pioneering development of therapies for neurodegenerative, hematologic, and autoimmune diseases.
Biogen's primary focus is on developing medicines for diseases with few or no treatment options. Over the years, it has secured the global marketing rights for a variety of significant products which address medical conditions like multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease.
One of Biogen's prominent products is TECFIDERA, a medicine for relapsing forms of MS. The company also made significant strides in SMA treatment with the development of SPINRAZA, a great achievement in the infant mortality combat.
Biogen's forward-thinking approach on R&D investment has led to a strong product pipeline. In March 2021, Biogen gained attention when its Alzheimer’s treatment, Aduhelm, became the first new Alzheimer’s medicine approved by the U.S. Food and Drug Administration (FDA) in nearly 20 years. However, the drug’s approval has been met with some controversy due to concerns about clinical trial data and its pricing.
In recent years, Biogen has also made strides in corporate responsibility, committing to carbon neutrality, and tackling diversity and inclusion. It has received recognition for its efforts in these areas, including featuring in the Dow Jones Sustainability World Index.
Biogen is publicly traded on the NASDAQ and forms part of the S&P 500 and NASDAQ-100. The company has shown significant growth and financial strength over the years with increasing revenue from a growing portfolio of drugs.
Under its current CEO Michel Vounatsos, Biogen continues to intensify its research and development activities, seeking to create new groundbreaking therapies, and deliver on its mission to improve the lives of those affected by serious diseases worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alamar Biosciences reported a 68% increase in Q3 2026 total revenue, driven by a 79% rise in consumables revenue and an improved gross margin of 61.5%. The company raised its full-year revenue guidance and highlighted strategic partnerships with UK Biobank and GSK to expand into new disease areas and advance large-scale studies. Alamar Biosciences is also developing its ARGO HTDx clinical instrument, with plans for FDA marketing authorization submission by the end of 2027.
DBV Technologies saw its shares rebound by nearly 9%, leading the SBF 120 despite a stagnating market and previous warnings about its going concern. This upturn follows recent quarterly accounts that highlighted financing needs and uncertainty beyond Q3 2027, alongside the submission of a BLA for its Viaskin Peanut patch to the FDA. The stock's recovery also coincides with a decrease in net declared short positions.
Beam Therapeutics reported a wider net loss of $134.405 million in Q3 2026, compared to $112.571 million in the same quarter last year, with license and collaboration revenue significantly decreasing. Despite the financial loss, the company holds $1.0 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations for at least the next 12 months. Beam Therapeutics also provided updates on its clinical pipeline, including positive data from its BEAM-302 trial for AATD, BEAM-301 for GSDIa, and progress in its risto-cel program for sickle cell disease.
Eads & Heald Wealth Management significantly increased its stake in Salesforce Inc. by 143.6% in the third quarter, acquiring 2,221 additional shares. This brings their total holdings to 3,768 shares valued at approximately $865,000, amidst high institutional ownership. Salesforce also reported strong quarterly earnings of $5.90 per share, surpassing consensus estimates, and analysts maintain a "Moderate Buy" rating with a target price of $278.98.
Argus has raised its target price for Royal Gold Inc. (RGLD) to $264.00, citing the company's business model of acquiring and managing precious metal royalties and streams, primarily focusing on gold. Royal Gold's strategy involves purchasing a percentage of metal production from mineral properties through an initial payment, without taking on the responsibilities of mining operations. The current stock price for RGLD is $235.99.
Myriad Genetics (MYGN) is set to announce its Q3 earnings, with analysts expecting a 7.1% year-on-year revenue decline after the company missed expectations last quarter. Despite past misses and declining revenue, investor sentiment in the therapeutics segment is positive, and Myriad Genetics' shares have risen by 29.5% over the last month. The company's average analyst price target is $4.49, against a current share price of $5.93.
Profound Medical (TSX:PRN) has signed a U.S. supply and distribution agreement with Cook Medical's iMRI Division, integrating its TULSA-PRO prostate ablation system into Cook's Copernicus program. This deal allows Cook to offer a turnkey prostate treatment solution by purchasing TULSA-PRO systems from Profound at a transfer price, while Profound retains direct relationships with customers for disposables and service contracts. Although financial terms like exclusivity and revenue targets were not disclosed, the partnership is expected to expand TULSA-PRO's reach in hospitals investing in MRI-targeted interventions.